-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Hengrui Medicine and Beilu Pharmaceutical Co.
, Ltd.
have entered the administrative examination and approval stage one after another by imitating 4 types of gadobutrol injections, and the first imitations are about to come out
.
Gadobutrol injection is a nuclear magnetic resonance gadolinium contrast agent.
In 2021, the sales revenue of the original research drug will be 418 million euros.
The original research company Bayer has monopolized the Chinese market for nearly ten years
.
, Ltd.
have entered the administrative examination and approval stage one after another by imitating 4 types of gadobutrol injections, and the first imitations are about to come out
.
Gadobutrol injection is a nuclear magnetic resonance gadolinium contrast agent.
In 2021, the sales revenue of the original research drug will be 418 million euros.
The original research company Bayer has monopolized the Chinese market for nearly ten years
.
Gadobutrol injection is a non-ionic contrast agent based on gadolinium, which is mainly used for magnetic resonance imaging examination of systemic lesions and whole-body magnetic resonance angiography examination
.
The original research drug of this product is Bayer's Jialexian, which was approved for marketing in the United States in March 2011 and in China in July 2012, and has monopolized the domestic market for nearly ten years
.
.
The original research drug of this product is Bayer's Jialexian, which was approved for marketing in the United States in March 2011 and in China in July 2012, and has monopolized the domestic market for nearly ten years
.
According to data from Minet.
com, Bayer's Galexian sales revenue will be 418 million euros in 2021.
In 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will sell terminal gadobutrol.
The amount exceeds 50 million yuan
.
com, Bayer's Galexian sales revenue will be 418 million euros in 2021.
In 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will sell terminal gadobutrol.
The amount exceeds 50 million yuan
.
Bayer gadobutrol global sales (million euros)
Source: Sales Database of Multinational Listed Companies on Minet.
com
com
The research and development of gadobutrol injection is difficult, and there are only a handful of domestic companies that have the courage to set foot there
.
.
Hengrui Medicine first submitted an application for imitation of the product in November 2012, and the review and approval ended in April 2020, but it passed by the first imitation
.
One month later, Hengrui Medicine once again submitted the application for the marketing of gadobutrol injection
.
Subsequently, Beilu Pharmaceuticals, Yangzijiang Pharmaceuticals, and Kelun Pharmaceuticals also submitted applications for the product's listing
.
.
One month later, Hengrui Medicine once again submitted the application for the marketing of gadobutrol injection
.
Subsequently, Beilu Pharmaceuticals, Yangzijiang Pharmaceuticals, and Kelun Pharmaceuticals also submitted applications for the product's listing
.
Today, the registration status of Hengrui Medicine and Beilu Pharmaceutical's gadobutrol injection has been changed to "under approval", and if it is successfully approved, it will be regarded as over-evaluation
.
.
As for who gets the first imitation, Hengrui Medicine is better in terms of the start time of the state , but it is also possible that the two companies are tied for the first imitation
.
That is to say, if everything goes well, Hengrui Medicine is determined to win the first imitation, and its leading position in contrast media will be further consolidated
.
.
That is to say, if everything goes well, Hengrui Medicine is determined to win the first imitation, and its leading position in contrast media will be further consolidated
.
Data source: Minet database, NMPA
Recently, Hengrui Medicine and Beilu Pharmaceutical Co.
, Ltd.
have entered the administrative examination and approval stage one after another by imitating 4 types of gadobutrol injections, and the first imitations are about to come out
.
Gadobutrol injection is a nuclear magnetic resonance gadolinium contrast agent.
In 2021, the sales revenue of the original research drug will be 418 million euros.
The original research company Bayer has monopolized the Chinese market for nearly ten years
.
, Ltd.
have entered the administrative examination and approval stage one after another by imitating 4 types of gadobutrol injections, and the first imitations are about to come out
.
Gadobutrol injection is a nuclear magnetic resonance gadolinium contrast agent.
In 2021, the sales revenue of the original research drug will be 418 million euros.
The original research company Bayer has monopolized the Chinese market for nearly ten years
.
Gadobutrol injection is a non-ionic contrast agent based on gadolinium, which is mainly used for magnetic resonance imaging examination of systemic lesions and whole-body magnetic resonance angiography examination
.
The original research drug of this product is Bayer's Jialexian, which was approved for marketing in the United States in March 2011 and in China in July 2012, and has monopolized the domestic market for nearly ten years
.
.
The original research drug of this product is Bayer's Jialexian, which was approved for marketing in the United States in March 2011 and in China in July 2012, and has monopolized the domestic market for nearly ten years
.
According to data from Minet.
com, Bayer's Galexian sales revenue will be 418 million euros in 2021.
In 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will sell terminal gadobutrol.
The amount exceeds 50 million yuan
.
com, Bayer's Galexian sales revenue will be 418 million euros in 2021.
In 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will sell terminal gadobutrol.
The amount exceeds 50 million yuan
.
Bayer gadobutrol global sales (million euros)
Source: Sales Database of Multinational Listed Companies on Minet.
com
com
The research and development of gadobutrol injection is difficult, and there are only a handful of domestic companies that have the courage to set foot there
.
.
Hengrui Medicine first submitted an application for imitation of the product in November 2012, and the review and approval ended in April 2020, but it passed by the first imitation
.
One month later, Hengrui Medicine once again submitted the application for the marketing of gadobutrol injection
.
Subsequently, Beilu Pharmaceuticals, Yangzijiang Pharmaceuticals, and Kelun Pharmaceuticals also submitted applications for the product's listing
.
.
One month later, Hengrui Medicine once again submitted the application for the marketing of gadobutrol injection
.
Subsequently, Beilu Pharmaceuticals, Yangzijiang Pharmaceuticals, and Kelun Pharmaceuticals also submitted applications for the product's listing
.
Today, the registration status of Hengrui Medicine and Beilu Pharmaceutical's gadobutrol injection has been changed to "under approval", and if it is successfully approved, it will be regarded as over-evaluation
.
.
As for who gets the first imitation, Hengrui Medicine is better in terms of the start time of the state , but it is also possible that the two companies are tied for the first imitation
.
That is to say, if everything goes well, Hengrui Medicine is determined to win the first imitation, and its leading position in contrast media will be further consolidated
.
.
That is to say, if everything goes well, Hengrui Medicine is determined to win the first imitation, and its leading position in contrast media will be further consolidated
.
Data source: Minet database, NMPA
Recently, Hengrui Medicine and Beilu Pharmaceutical Co.
, Ltd.
have entered the administrative examination and approval stage one after another by imitating 4 types of gadobutrol injections, and the first imitations are about to come out
.
Gadobutrol injection is a nuclear magnetic resonance gadolinium contrast agent.
In 2021, the sales revenue of the original research drug will be 418 million euros.
The original research company Bayer has monopolized the Chinese market for nearly ten years
.
, Ltd.
have entered the administrative examination and approval stage one after another by imitating 4 types of gadobutrol injections, and the first imitations are about to come out
.
Gadobutrol injection is a nuclear magnetic resonance gadolinium contrast agent.
In 2021, the sales revenue of the original research drug will be 418 million euros.
The original research company Bayer has monopolized the Chinese market for nearly ten years
.
Gadobutrol injection is a non-ionic contrast agent based on gadolinium, which is mainly used for magnetic resonance imaging examination of systemic lesions and whole-body magnetic resonance angiography examination
.
The original research drug of this product is Bayer's Jialexian, which was approved for marketing in the United States in March 2011 and in China in July 2012, and has monopolized the domestic market for nearly ten years
.
.
The original research drug of this product is Bayer's Jialexian, which was approved for marketing in the United States in March 2011 and in China in July 2012, and has monopolized the domestic market for nearly ten years
.
According to data from Minet.
com, Bayer's Galexian sales revenue will be 418 million euros in 2021.
In 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will sell terminal gadobutrol.
The amount exceeds 50 million yuan
.
hospital hospital hospitalcom, Bayer's Galexian sales revenue will be 418 million euros in 2021.
In 2020, China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will sell terminal gadobutrol.
The amount exceeds 50 million yuan
.
Bayer gadobutrol global sales (million euros)
Source: Sales Database of Multinational Listed Companies on Minet.
com
com
The research and development of gadobutrol injection is difficult, and there are only a handful of domestic companies that have the courage to set foot there
.
.
Hengrui Medicine first submitted an application for imitation of the product in November 2012, and the review and approval ended in April 2020, but it passed by the first imitation
.
One month later, Hengrui Medicine once again submitted the application for the marketing of gadobutrol injection
.
Subsequently, Beilu Pharmaceuticals, Yangzijiang Pharmaceuticals, and Kelun Pharmaceuticals also submitted applications for the product's listing
.
.
One month later, Hengrui Medicine once again submitted the application for the marketing of gadobutrol injection
.
Subsequently, Beilu Pharmaceuticals, Yangzijiang Pharmaceuticals, and Kelun Pharmaceuticals also submitted applications for the product's listing
.
Today, the registration status of Hengrui Medicine and Beilu Pharmaceutical's gadobutrol injection has been changed to "under approval", and if it is successfully approved, it will be regarded as over-evaluation
.
.
As for who gets the first imitation, Hengrui Medicine is better in terms of the start time of the state , but it is also possible that the two companies are tied for the first imitation
.
That is to say, if everything goes well, Hengrui Medicine is determined to win the first imitation, and its leading position in contrast media will be further consolidated
.
Pharmaceutical pharmaceutical pharmaceutical enterprise enterprise enterprise.
That is to say, if everything goes well, Hengrui Medicine is determined to win the first imitation, and its leading position in contrast media will be further consolidated
.
Data source: Minet database, NMPA
